Alberto Arranz - Concepedia

Author

Alberto Arranz

Hospital Universitario Príncipe de Asturias ORCID

Also Known As

A Arranz, A Torralba Arranz, A. Arranz, A. Jou, Alberto Arranz, Alberto Sanz Arranz, Antonio Ismael Ruiz Arranz, C Quereda, C. Quereda, C. Tural

Publications

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Príncipe de Asturias Instituto Ramón y Cajal de Investigación Sanitaria Universidad de Alcalá Universidad Complutense de Madrid Universidad Autónoma de Madrid

About

Alberto Arranz is an author at Hospital Universitario Príncipe de Asturias specializing in epidemiology, primary immunodeficiency, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	68
2	Epidemiology	1	1	68
3	Immunology	1	1	68
4	Hiv	1	1	68
5	Primary Immunodeficiency	1	1	68

Alberto Arranz

Publications

766

Citations

H-Index

Page 1

	Year	Citations
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV Federico Pulido, José Ramón Arribas, Rafaël Delgado, AIDS	2008	154
Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression José Ramón Arribas, Federico Pulido, Rafaël Delgado, JAIDS Journal of Acquired Immune Deficiency Syndromes	2005	149
Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis José Ramón Arribas, Rafaël Delgado, Alberto Arranz, JAIDS Journal of Acquired Immune Deficiency Syndromes	2009	108
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study Sergio Serrano‐Villar, Javier Martínez‐Sanz, Raquel Ron, The Lancet HIV Primary ImmunodeficiencyTreatment And PreventionHuman RetrovirusImmunologyFirst-line Antiretroviral Therapy	2020	68
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression Federico Pulido, Ignacio Valero, Rafaël Delgado, Antiviral Therapy	2009	60
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression Federico Pulido, Rafaël Delgado, Ignacio Valero, Journal of Antimicrobial Chemotherapy	2008	41
Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events Javier Martínez‐Sanz, Jorge Díaz-Álvarez, Marta Rosas Cancio-Suárez, EBioMedicine	2023	32
Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients Jorge Monserrat, Ana M. Gómez-Lahoz, Miguel Á. Ortega, International Journal of Molecular Sciences	2022	31
Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus Load Paloma Gil, Miguel Górgolas, Vicente Estrada, Clinical Infectious Diseases	2004	28
A Predictive Model and Risk Factors for Case Fatality of COVID-19 Melchor Álvarez‐Mon, Miguel Á. Ortega, Óscar Gasulla, Journal of Personalized Medicine	2021	27

Page 1